Fatigue and sensorimotor instability Neurologically controlled conversion of post-COVID-19 patients, 2024, Urban et al

[Mij]

Abstract
Background: For the treatment of the symptoms of post-COVID-19 syndrome, no causal therapy is currently widely recommended according to evidence-based criteria. The overarching goal of the intervention study over a 3-year period (Q1-2021-Q4-2023) was to evaluate the changes in the key symptoms of fatigue and sensorimotor instability through individualized stress-controlled training therapy and through intensified cognitive behavioral therapy.

Material and methods: In the 3‑year period 407 vaccinated nucleocapsid positive patients were treated at the Post-COVID-19 Center Lausitz (Senftenberg). In 78 (around 19%) fatigue/immunometabolic depression and sensorimotor instability were identified as the leading syndromes. The evaluation of the individualized stress-controlled training therapy was based on the specific post-COVID-19 syndrome and motor fatigue parameters. The secondary psychosomatic syndrome was assessed using cognitive fatigue parameters and cognitive behavioral therapy instruments. The investigation of -parameters influencing behavior took place in Q2-2023-Q4-2023 with a guide-supported qualitative interview among the participants.

Results: The post-COVID-19 key symptoms "fatigue," "sensorimotor instability," "neuropsychiatric symptoms," "cardiac/autonomic dysfunction," and "pain" improved significantly in the overall cohort and in the gender-specific analysis. A deterioration occurred in "secondary psychosomatic symptoms". A therapeutic effect was demonstrated for all motor fatigue parameters for the entire cohort using the Cohen's d value. An intensification of cognitive behavioral therapy achieved positive effects through an increasing development of the patients' own activity and their self-control using persuasion and gamification.
LINK

 

[Haveyoutriedyoga]

For the computer-controlled training system used by the PCZ, a training therapy had been developed in advance in 2018 …[…]… the load control of which is based on a real-time measurement of the strain on the affected patient [ 15 , 17 ]. This made it possible to provide dosed training stimuli to immunologically and/or otherwise stressed, energetically depleted patients with fatigue/immunometabolic depression [ 1 ], which were previously considered contraindicated.

Without this control mechanism, crash/PEM occurs and thus a further severe deterioration in the patient's performance (e.g. in multiple sclerosis, in hemato-oncology and currently in the context of immunotherapy of metastatic tumors).

 

[Haveyoutriedyoga]

What is immunometabolic depression?

I didn’t know MS and cancer included PEM…

 

[Mij]

What is immunometabolic depression?

The IMD dimension is hypothesized to reflect a clustering of specific depressive symptoms on the atypical spectrum indicating altered energy homeostasis (e.g. increased appetite/weight, hypersomnia, extreme fatigue and leaden paralysis) and inflammatory and metabolic dysregulations (e.g. increased inflammatory status and disruption of energy-regulating neuroendocrine signalling)

IMD has not been proposed as a new established clinical subtype of depression, but rather as a theoretical dimension to be investigated for its clinical usefulness. Note that the term ‘immune–metabolic’ is used in the immunological literature to refer to the interplay between the immune system and cellular metabolic processes, which is different from what we are referring to with the IMD concept.
LINK

 

[rvallee]

"The king is alive? Long live the king?"

Are they pretending not to know that the thing they are testing is the "causal therapy is currently widely recommended according to evidence-based criteria"? Or are they genuinely ignorant? I doubt it. It's not plausible. Not even close.

For starters there is a heavy selection effect for anyone willing to participate in something like this, the woowoo level is about on par with the LP. About the same selection effect as clients to a homeopathic clinic being more likely to report effectiveness from their very expensive water than a random selection. So it's not even a randomized trial, let alone controlled, even less so properly controlled.

Aside from translation issues from its original German, this is all very weird and meandering, filled with odd opinions and voodoo nonsense. Even AI slop isn't as weird most of the time. These people don't have a clue what they're doing here.

 

[Maat]

It doesn't say when this 3 year study was submitted for peer review. I suggest this paper should be read in tandem with this one https://www.s4me.info/threads/trust...ent-physical-symptoms-2024-lewis-et-al.40879/

The Persistent physical symptoms services treats MS, IBS and Chronic Fatigue Syndromes patients. Not by illness or disease but by symptom.

This is happening around the UK:
Persistent Physical Symptoms Research and Treatment Unit | King's College London
Persistent Physical Symptoms… | NHS Physical Health Psychology Cumbria
Persistent physical symptoms service (PPSS) - Tees Esk and Wear Valley NHS Foundation Trust
Persistent Physical Symptom Service > CYPS Glos Health & Care NHS



From the translated version:

Background

For the treatment of the symptoms of post-COVID-19 syndrome, no causal therapy according to evidence-based criteria is currently widely recommended. The overarching goal of the intervention study was to evaluate the changes in the main symptom fatigue and sensorimotor instability through individualized stress-controlled exercise therapy as well as intensified cognitive behavioral therapy over a 3-year period (Q1-2021 to Q4-2023).

Would this mean first quarter of 2021 as the beginning of the study?

As haveyoutriedyoga highlights:

For the computer-controlled training system used by the PCZ, a training therapy had been developed in advance in 2018 …[…]… the load control of which is based on a real-time measurement of the strain on the affected patient [ 15 , 17 ]. This made it possible to provide dosed training stimuli to immunologically and/or otherwise stressed, energetically depleted patients with fatigue/immunometabolic depression [ 1 ], which were previously considered contraindicated.

Without this control mechanism, crash/PEM occurs and thus a further severe deterioration in the patient's performance (e.g. in multiple sclerosis, in hemato-oncology and currently in the context of immunotherapy of metastatic tumors).

​

Remember, remember - "There is a way". 2018 to September 2024 German research and October 2024 English research, and entirely explains the continued delays in the ME/CFS Delivery plan.

This is a deliberate circumvention of the NICE Guideline. If NHSE and associated ICBs can do this for one illness, they can do it for all. Not treating the illness, just the individual symptoms.

That's it, as far as I'm concerned.

​